Bristol Myers Squibb CEO Chris Boerner expressed concern over the U.S. losing its measles elimination status, linking it to a broader erosion of the nation's scientific and healthcare ecosystem. He emphasized that the U.S.'s leadership in developing new medicines, including vaccines, is not guaranteed and depends on a robust public-private partnership, regulatory efficiency, and respect for science. Boerner also highlighted inefficiencies in the healthcare system, particularly the role of middlemen in drug pricing, and advocated for reforms that would allow for more value-based payment models. AI
RANK_REASON CEO commentary on industry trends and policy implications, not a direct company announcement or product release.
- Albert Bourla
- Bolivia
- Bristol Myers Squibb
- Canada
- Chris Boerner
- Cristian Massacesi
- Detroit
- Diane Brady
- Fortune 500 Innovation Forum
- measles
- Mexico
- Pan American Health Organization
- Pfizer
- United States
- United States Department of Health and Human Services
- United States Food and Drug Administration
- NIH
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →